Get all premium features to the best stock analysis tool

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.

Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

EAT, PAHC and NVST made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 12th, 2026.

Envista (NVST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?